This is a very important question. You have to know that there is a limitation in this study, because when we created and took this study, the use of adjuvant PARP inhibitor was not yet approved, so there are no patients that received adjuvant PARP inhibitor in this setting. But for sure, the use of a vascular suppression in the first part of the adjuvant treatment is very important and now we have this data that support the use of this...
This is a very important question. You have to know that there is a limitation in this study, because when we created and took this study, the use of adjuvant PARP inhibitor was not yet approved, so there are no patients that received adjuvant PARP inhibitor in this setting. But for sure, the use of a vascular suppression in the first part of the adjuvant treatment is very important and now we have this data that support the use of this. We cannot enlarge these results also in the population that receive adjuvant PARP inhibitor because we have not the data in this moment.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
